August 29, 2019 10:10 AM EDT
News Briefing

Es­pe­ri­on re­leas­es pos­i­tive PhII re­sults; Safe­ty warn­ings at In­dia, Chi­na man­u­fac­tur­ing sites spell trou­ble for glob­al sup­ply chain

ENDPOINTS

→ Af­ter lin­ing up a new $200 mil­lion fund­ing deal for the pro­ject­ed com­mer­cial launch of be­mpe­doic acid next year, Es­pe­ri­on an­nounced to­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times